8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2016

OncoSec Medical Incorporated

(Exact name of registrant as specified in its charter)

Nevada	000-54318	98-0573252
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

5820 Nancy Ridge Drive San Diego, CA	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (855) 662-6732

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.02 Termination of a Material Definitive Agreement.

OncoSec Medical Incorporated (the “Company”) and Rev.1 Engineering Inc. (“Rev.1”) entered into a Research and Development Services Agreement effective March 6, 2015 (the “Agreement”). The Company and Rev.1 entered into an Amendment No. 1 to Research and Development Services Agreement effective February 17, 2016 (the “Amendment,” and collectively with the Agreement, the “Amended Agreement”). Under the Amended Agreement, Rev.1 has provided research and development services to the Company relating to certain Company device development efforts.

As part of the Company’s normal business practice of reviewing the cost and efficiency of its programs, the Company has terminated the Amended Agreement in a notice to Rev.1 dated June 29, 2016. The termination will be effective July 31, 2016 (the “Termination Date”). On the Termination Date, as a termination fee, the Company will forfeit to Rev.1 any remaining portion of the deposit that was pre-paid under the Amended Agreement. As of May 31, 2016, approximately $203,249 of the deposit remained outstanding. As provided in the Amended Agreement, ten percent of each invoice will continue to be applied against and will thereby reduce the deposit amount that the Company will forfeit on the Termination Date.

The Company will now work with Rev.1 to transition its projects from Rev.1 to the Company in advance of the Termination Date.

The foregoing description of the Amended Agreement does not purport to be complete and is qualified in its entirety by the full text of the Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by this reference, and by the full text of the Amendment, which is attached as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
10.1	Research and Development Services Agreement, dated March 6, 2015, by and between the Company and Rev.1 Engineering Inc.
10.2	Amendment No. 1 to Research and Development Services Agreement, dated February 17, 2016, by and between the Company and Rev.1 Engineering Inc.

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 1, 2016	OncoSec Medical Incorporated
	By:	/s/ Punit Dhillon
	Name:	Punit Dhillon
	Title:	President and Chief Executive Officer (Principal Executive Officer)

- 3 -

EX-10.1

RESEARCH AND DEVELOPMENT SERVICES AGREEMENT

THIS RESEARCH AND DEVELOPMENT SERVICES AGREEMENT (“Agreement”) is being entered into as of this 6th day of March, 2015 (the “Effective Date”), by and between OncoSec Medical Incorporated, a Nevada Corporation with a principal place of business at 9810 Summers Ridge Rd., Ste. 110, San Diego, CA 92121 (the “Company”), and Rev.1 Engineering Inc., a California Corporation, having a principal place of business at 41693 Date Street, Murrieta, CA 92562 (“Rev.1”). Rev.1 and Company are at times referred to individually as a “Party” and jointly as the “Parties.”

Recitals

WHEREAS, Company desires to engage Rev.1, and Rev.1 has agreed to be engaged by Company, to provide the services set forth on Exhibit “A” attached hereto and incorporated by reference (“Services”); and,

WHEREAS, the Services to be performed by Rev.1 for and on behalf of the Company relate to the research and development products which are described in Exhibit “A,” which description is incorporated by reference (the “Products”).

Agreement

NOW, THEREFORE, in consideration of the following mutual promises, representations, conditions, and covenants, the Parties hereby agree as follows:

1. Recitals. The Recitals set forth above are hereby incorporated by reference into this Agreement, as if fully set forth herein.

2. Definitions. Capitalized terms used in this Agreement and not otherwise defined shall have the following meanings:

(a) “Company Documents and Materials” shall refer to all documents or other media, whether tangible or intangible, that contain or embody Proprietary Information, as defined below, or any other information concerning the business, operations or plans of the Company, whether such documents or media have been prepared by Company, or by others on behalf of the Company. Company Documents and Materials include, but are not limited to, blueprints, drawings, photographs, charts, graphs, notebooks, tests, test results, experiments, customer lists, computer disks, tapes or printouts, sound recordings and other printed, electronic, typewritten or handwritten documents or information, sample products, prototypes and models.

(b) “Inventions” means, the Product being developed pursuant to this Agreement resulting from the performance of the Services. Unless specifically included on Exhibit “A” as part of the Services to be performed, the term “Inventions” does not include any software programs or subroutines, source or object code, algorithms, improvements, works of authorship, technology, designs, formulas, ideas, processes, techniques, methodology, know-how and data, whether or not patentable or copyrightable, made, discovered, conceived, reduced to practice, or developed by Rev.1, which are not an integral part of the Product even if developed or discovered by Rev. 1 in designing or developing the Product.

(c) “Proprietary Information” means information relating to the Services or the Product which is developed, created, or discovered by or on behalf of the Company, or which became or will become known to, or was or is conveyed to the Company pursuant to this Agreement, which has commercial value in Company’s business, whether or not patentable or copyrightable, including, without limitation: (i) specifically developed software programs, subroutines, source and object code, algorithms, (ii) specifically developed designs, technology, know-how, processes, data, ideas, techniques; (iii) works of authorship; and (iv) product development plans. Propriety Information will also included any information provided by Company to Rev. 1 relating to: (i) customer lists; (ii) terms of compensation and performance levels of the Company’s employees and consultants; (iii) Company’s customers; (iv) other information concerning the Company’s actual or anticipated business, research or development: or (v) information which is received in confidence by or for the Company from any other person or entity by Rev. 1 which is marked “Confidential.” However, Proprietary Information does not apply to any information known to Rev. 1 prior to the signing of this Agreement or which is common knowledge or otherwise published by Company.

(d) “Services” means those services as set forth on Exhibit “A,” to be performed by Rev.1 for and on behalf of the Company related to the research and development of the Product.

(e) “Deliverables” means all work product and related materials prepared and developed by Rev. 1 in connection with this Agreement, including, but not limited to, the preliminary prototype components, initial design specifications and drawings, documentation of materials and processes used to fabricate the prototypes, summary of bench testing, and the materials related to the Services provided under this Agreement, including, but not limited to, all materials, prototypes and files.

3. Research and Development Services. Rev.1 shall use commercially reasonable efforts, and devote sufficient time, attention and provide qualified personnel, to perform the Services, in accordance with the schedule set forth on Exhibit “A.” Rev.1 does not guarantee that the Product can be developed. If the Product cannot be developed using commercially reasonable efforts, Company will still be required to make all payments for the Services pursuant to the terms of this Agreement.

4. Compensation.

(a) Company shall pay Rev.1 for the Services to be performed under this Agreement the compensation set forth on Exhibit “B,” including any hourly cost for labor performed as part of the Services (the “Labor Costs”). Company acknowledges that the Labor Costs do not include the cost of capital equipment, outside services or First in Man (“FIM”) Product incurred in connection with Rev.1’s performance of the Services (the “Excluded Costs”). Excluded Costs will be the sole and exclusive responsibility of the Company, payable in accordance with the schedule set forth on Exhibit “B” of such Excluded Costs. Company will also pay to Rev. 1 any and all other Compensation in accordance with the schedule set forth on Exhibit “B”. Company will pay to Rev. 1 travel time (door to door) related to the performance of the Services at the Labor Costs rates set forth on Exhibit “B.”

(b) In addition, the Company will reimburse Rev.1 for all reasonable, documented and actual expenses, including, without limitation, actual travel expenses (airfare, hotel, rental car, meals, parking, etc.) incurred by Rev.1 in connection with its performance of the Services.

(c) The Company shall pay to Rev.1 all amounts due under this Section 4 within fifteen (15) calendar days of the Company’s receipt from Rev.1 of Rev. 1’s invoice.

(d) Rev.1 has the option to invoice expenses twice per month if Rev.1 reasonably determines the carrying costs of these expenses warrants doing so.

(e) The Company will pay all capital expenses directly to the vendor responsible for delivering the capital items.

5. Term. The term of this Agreement shall commence on the Effective Date and continue until the earlier of: (i) Rev.1’s completion of the Services; (ii) termination by either Party, for any reason, upon giving not less than thirty (30) days’ written notice to the other Party; (iii) immediately upon a material breach of this Agreement by a Party, if such breach is not cured within ten (10) days following notice of such breach; (iv) by Rev. 1 in the event that payment is not received within fifteen (15) days of an invoice being due and payable by Company; or (v) the dissolution, voluntary or involuntary bankruptcy of either Party, or assignment by either Party of all or substantially all of its assets for the benefit of creditors. Notwithstanding the termination of this Agreement, any liability or obligation of either Party which may have accrued prior to such termination, shall continue in full force and effect, including but not limited to the rights and obligations of the Parties under Sections 4, 5(a), 6, 7, 8, 11, 13, and 21 of this Agreement.

(a) Cancelation Fee. Given the nature of the Services, Company acknowledges that Rev. 1 will be making a substantial initial investment of time, effort and funds in order to begin to provide the Services and attempt to develop the Product. Some of these costs are amortized by Rev. 1 throughout the entire term of this Agreement. If Company terminates this Agreement before the end of the term, Company will pay in full for all services & expenses not yet paid and will then also forfeit the remaining Deposit held by Rev.1. If Rev.1 terminates this agreement, after payment is made by Company for all outstanding balances, Rev.1 will refund the remaining Deposit, if any.

6. Confidentiality of Proprietary Information.

(a) Nature of Information. Rev.1 acknowledges that the Company possesses and will possess Proprietary Information which is important to its business. Rev.1 further acknowledges that Rev.1’s engagement creates a relationship of confidence and trust between the Company and Rev.1 with respect to Proprietary Information.

(b) Property of the Company. All of Company Documents and Materials, all of Company’s Proprietary Information and all patents, patent rights, copyrights, Company trade secret, Company trademarks and other Company intellectual property rights, are and shall be the sole property of the Company. Rev.1 assigns to the Company any and all rights, title and interest Rev.1 may acquire in any such Company Proprietary Information or Company Documents and Materials, in performing the Services, to the Company.

(c) Confidentiality. At all times, except as may be necessary in performing the Services, both during the term of Rev.1’s engagement by the Company and after Rev.1’s termination, Rev.1 shall not use or disclose any Proprietary Information or anything relating to it without the prior written consent of the Company.

(d) Compelled Disclosure. In the event that Rev.1 is requested in any legal proceeding to disclose any Proprietary Information, Rev.1 shall give the Company prompt notice of such request so that the Company may seek an appropriate protective order. If, in the absence of a protective order, if Rev.1 is compelled by any Court of competent jurisdiction to disclose such Proprietary Information, Rev.1 may disclose such information without liability.

(e) Records. Rev.1 agrees to make and maintain adequate and current written records, of all Inventions, trade secrets and works of authorship assigned or to be assigned to the Company pursuant to this Agreement.

(f) Handling of the Company Documents and Materials. Except as may be necessary in performing the Services, Rev.1 shall not remove any Company Documents and Materials from the business premises of the Company or deliver any Company Documents and Materials to any person or entity outside the Company. Rev.1 immediately upon termination of this Agreement, or if so requested by the Company, will return all Company Documents and Materials, apparatus, equipment and other physical property, excepting that Rev. 1 may maintain one copy of such material for its business records subject to the non disclosure terms of this Agreement.

7. Inventions.

(a) Disclosure. Rev.1 shall promptly disclose in writing to Company all discoveries and new developments made during the term of Rev.1’s engagement with the Company relating to the Services. Rev.1 will disclose to Company any discoveries, or inventions made, discovered, conceived, reduced to practice or developed by Rev. 1, either alone or jointly with others, within six (6) months after the termination of this Agreement which result, in whole or in part, relating to the Services. Such disclosures shall be received by the Company in confidence, to the extent such inventions are not assigned to the Company pursuant to subsection (b) below, and do not extend the assignments set forth below.

(b) Assignment of Inventions to the Company. All Inventions which Rev.1 makes, discovers, conceives, reduces to practice or develops (in whole or in part, either alone or jointly with others) in performing the Services shall be the sole property of the Company, to the maximum extent permitted by law and Rev.1 will assign to the Company all of its rights, title and interest to such Inventions. Unless specifically included on Exhibit “A” as part of the Services to be performed, such assignment does not apply to any software programs or subroutines, source or object code, algorithms, improvements, works of authorship, technology, designs, formulas, ideas, processes, techniques, methodology, know-how and data, whether or not patentable or copyrightable, made, discovered, conceived, reduced to practice, or developed by Rev.1, which are not developed or discovered by Rev. 1 in designing or developing the Product.

(c) Works Made for Hire. Rev.1 acknowledges that the Company shall be the sole owner of all patents, patent rights, copyrights, trade secret rights, trademark rights and all other intellectual property rights in connection with the Inventions. Rev.1 further acknowledges that such Inventions, including, without limitation, any computer programs, programming documentation and other works of authorship, are “works made for hire” for purposes of the Company’s rights under patent or copyright laws. Rev.1 hereby assigns to the Company any and all rights, title and interest Rev.1 may have or acquire in such Inventions. If in the course of Rev.1’s engagement with the Company, Rev.1 incorporates into a Company product, process or machine a prior invention or improvement not related to the Services that is owned by Rev.1 or in which Rev.1 has an interest, the Company is granted and shall have a non-exclusive, royalty-free, irrevocable, perpetual, sublicensable, worldwide license to make, have made, modify, use, market, sell and distribute such prior invention as part of or in connection with such Product. Company will be responsible for obtaining all intellectual property protection, including all licenses, trademarks and copyrights.

(d) Cooperation. Rev.1 will perform, all acts necessary to permit and assist Company, at Company’s expense, in further evidencing and perfecting the assignments made to the Company under this Agreement and in obtaining, maintaining, defending and enforcing patents, patent rights, copyrights, trademark rights, trade secret rights or any other rights in connection with such Inventions and improvements related to the Services in any and all countries. Such acts may include, without limitation, execution of documents and assistance or cooperation in legal proceedings.

8. Non-Competition. During the term of this Agreement and for three years thereafter, Rev.1 shall not, with or without consideration, develop a product similar to the Product, for any person, business, firm or corporation. Rev.1 is not precluded from providing services to any person, business, firm or corporation engaged in any business competitive with the business conducted by the Company, so long as the services being provided do not include developing a similar product to the Product developed pursuant to this Agreement.

9. Arrangement Non-Exclusive. Except for the restrictions set forth above in this Agreement, this is not an exclusive agreement and Rev. 1 is not restricted from providing similar services for any other existing or potential customer.

10. Independent Contractor. The Parties acknowledge that Rev.1 shall, at all times, be acting and performing as an independent contractor. Nothing in this Agreement is intended to create an employer/employee relationship or a joint venture relationship between the Parties. Rev.1 is not eligible for any compensation, fringe benefits, pension, workers’ compensation, sickness or health insurance benefits, or other similar benefits accorded employees of the Company. Company will not withhold any sums for income tax, unemployment insurance, social security, or any other withholding pursuant to any law or requirement of any governmental body on behalf of Rev.1. Rev.1 acknowledges that the Company has no obligation under local, state, or federal laws regarding Rev.1 and that the total commitment and liability of the Company in regard to any arrangement with, or work performed by, Rev.1 hereunder is to compensate Rev. 1 as set forth in Section 4 hereof.

11. Maintenance of Records. During the term of this Agreement and for five (5) years after the completion of the Services, Rev.1 shall make available, upon written request of the Company or its designee, any records maintained by Rev.1 regarding any of the Services performed hereunder by Rev.1.

12. No Authority to Bind. Rev.1 shall have no power or authority to execute any agreements or contracts for or on behalf of the Company or to bind the Company in any other manner.

13. Liability Limitation. Without limiting any other provisions hereunder, under no circumstances shall Rev.1 be liable to Company with respect to this Agreement for any consequential, indirect, exemplary, special or incidental damages of any kind regardless of the form of action, whether in contract, tort (including negligence), strict liability, or otherwise. Rev. 1’s liability for any other cause of action will be limited to thirty percent (30%) of the compensation already paid to Rev.1, even if Rev.1 has been advised of the possibility of such damages.

14. No Assignment. This Agreement may not be assigned by either Party without the written consent of the other party.

15. Severability. If one or more provisions of this Agreement are held to be unenforceable by a Court of competent jurisdiction, then such provisions shall be excluded from this Agreement and the balance of the Agreement shall remain in full force and effect.

16. Binding Effect. This Agreement shall inure to the benefit of and are binding upon, the Parties and their respective successors and permitted assigns.

17. Amendment. This Agreement may only be amended in writing signed by both Parties.

18. Notice. All notices and other communications under this Agreement shall be in writing and shall be deemed to have been duly given on date of delivery, if delivered personally, or on the date delivered if by overnight mail, or certified mail, postage pre-paid, if sent pre-paid and addressed as follows:

If to Rev. 1:	Rev. 1 Engineering Inc.
	Attn: Phillip Burke, COO
	41693 Date Street
	Murrieta, CA 92562
If to Company:	OncoSec Medical Incorporated
	Legal Department
	Attn: Sheela Mohan-Peterson
	9810 Summers Ridge Rd., Ste. 110
	San Diego, CA 92121

A Party may change its address by providing notice to the other Party.

19. Arbitration.

Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, including, but not limited to, the validity and enforceability of this Agreement under all Federal and State Laws or otherwise, will be settled by binding arbitration in accordance with the appropriate Rules of the Judicial Arbitration and Mediation Services (JAMS), and judgment upon the award rendered may be entered in any court having jurisdiction thereof. Any such arbitration award will be binding on the Parties. Such arbitration will be conducted before JAMS in Ontario, California.

The Parties may seek or obtain any provisional remedy, including, but not limited to, prejudgment attachment and injunctive relief, in a court of competent jurisdiction without waiving the right to arbitration.

Within ten (10) days of the service of a claim or demand for arbitration by a Party upon the other Party, the Parties will select from JAMS a mutual arbitrator to hear this matter. If the Parties are unable to select a mutually acceptable arbitrator, then each Party will designate in writing and appoint one arbitrator from JAMS and these two arbitrators will then select a third arbitrator from JAMS, who will then serve as the sole arbitrator in this matter. Each Party will pay their or its own party-appointed arbitrator fees and expenses in connection with the arbitration, subject to recovery by the prevailing Party, as set forth in Paragraph 22 below. The Parties acknowledge that they are willing to have the third arbitrator paid at his or her normal hourly rate, which cost is to be split between the Parties.

The arbitrators will be required to decide all matters in accordance with the applicable law and in accordance with the provisions of this Agreement.

20. Entire Agreement. This Agreement constitutes the entire agreement between the Parties and supersedes any and all other written or oral agreements between the Parties with respect to the subject matter of this Agreement.

21. Governing Law and Consent to Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to its principles of conflicts of laws. The Parties hereto irrevocably submit to the exclusive jurisdiction of the state and federal courts sitting in the County of Riverside, State of California for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. The above provision in no ways affects the provisions of Section 19 pertaining to Arbitration.

22. Attorney’s Fees. If any action is necessary to enforce any provision of this Agreement, the prevailing party shall be entitled to recover all of its costs, including all attorney fees and court costs.

23. Counterparts. This Agreement may be executed in one or more counterparts with either an original or facsimile or pdf signature considered to be an original, and all of which together shall constitute one and the same instrument.

In Witness Whereof, the Company and Rev.1 have made this Agreement effective as of the Effective Date.

Rev.1 Engineering Inc.	Oncosec Medical Incorporated
By:	By:
Name:	Name:	Punit Dhillon
Title:	Title:	President & CEO

Exhibit A

A. Scope of Work

1. Research & Product Development Project 1

2. Research & Product Development Project 2

B. Services to be Provided

1. Research, Development, Testing and Regulatory Filing of Project 1

2. Research, Development, Testing and Regulatory Filing of Project 2

C. PRODUCT DESCRIPTION

1. Project 1

2. Project 2

D. Project Deliverables

1. All Product Development Phase Reviews (through regulatory filing) for both Products

EXHIBIT A

Exhibit B – Hourly

Pricing and Payment Terms

●   Rev.1 Labor & Expense Estimate: $3,383,000

PURCHASE ORDER

Company will place a purchase order with Rev.1 in the amount of Three Million, Three Hundred and Eighty-Three Thousand dollars ($3,383,000). This is the labor and materials estimate and includes the initial deposit described below.

INITIAL DEPOSIT

Company will pay an initial deposit to Rev.1 in the amount of Three Hundred and Fifty Thousand dollars ($350,000) (the “Deposit”) upon signing of this contract and prior to projects being initiated. Thereafter, 10% of each monthly invoice shall be offset by the Deposit, reducing the Deposit accordingly. The Deposit will be consumed over the project in a monthly frequency, at the rate above, until the projects are complete. Any remaining Deposit will be applied to the final invoice for the projects. Except as provided in Section 5(a), upon conclusion of the Agreement and after payment of the final invoice, any remaining portion of the Deposit will be returned to Company.

PAYMENT TERMS

This is a time and materials contract. Monthly invoices will be provided for services provided. Payment is due within fifteen (15) calendar days of receipt of such invoice.

LATE PAYMENT PENALTY

A late payment penalty will be imposed following any payments that are deemed late as per payment terms section above. A late payment penalty of two percent (2%) of the invoiced amount will be immediately due.

EXHIBIT B

EX-10.2

Amendment No. 1 to

Research and Development Services Agreement

This Amendment No. 1 to Research and Development Services Agreement (this “Amendment”) dated as of February 17th, 2016 (the “Amendment Date”) is entered into between OncoSec Medical Incorporated, a Nevada corporation (hereinafter, “Company”), having offices at 5820 Nancy Ridge Drive, San Diego, California 92121, and Rev.1 Engineering Inc., a California corporation (hereinafter, “Rev.1”), having offices at 41693 Date Street, Murrieta, California 92562, with respect to the following facts:

A. The Parties entered into the Research and Development Services Agreement dated as of March 3, 2015 (the “Agreement”). All terms used, but not defined, herein shall have the respective meanings set forth in the Agreement.

B. The Parties now desire to amend the Agreement in certain respects on the terms and conditions set forth below.

Now Therefore, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties hereby amend the Agreement and otherwise agree as follows:

1. Amendments.

1.1 Exhibit A to the Agreement is hereby amended and restated to read in full as set forth on Attachment 1 hereto.

1.2 Exhibit B to the Agreement is hereby amended and restated to read in full as set forth on Attachment 2 hereto.

1.3 Attachment 3 hereto is hereby incorporated into the Agreement as Exhibit C.

1.4 Section 4(a) of the Agreement is hereby amended by deleting the words “Exhibit ‘B’” and replacing them with “Exhibit ‘A’”.

2. Miscellaneous.

2.1 This Amendment shall be effective for all purposes as of the Amendment Date. Except as otherwise expressly modified by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms.

2.2 This Amendment may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same agreement.

2.3 This Amendment has been executed in the State of California and its validity, construction, and all rights under it shall be governed by the laws of the State of California without reference to conflicts of law principles.

Page 1 of 8

In Witness Whereof, the Parties have duly executed and delivered this Amendment as of the Amendment Date.

Rev.1 Engineering Inc.		OncoSec Medical Incorporated
By:		By:
	Phillip Burke		Punit S. Dhillon
	COO		President and CEO

Page 2 of 8

Attachment 1

Exhibit A – Services; Compensation

A. Services

Services (and related Products) shall be described in Statements of Work in substantially the form attached hereto as Exhibit B. As shown on Exhibit B, each Statement of Work should include, among other things, a term, a description of Services to be performed, deliverable(s) (or percentage progress toward deliverable(s)), and a budget. Each Statement of Work executed under this Agreement shall be incorporated into this Agreement and be governed by its terms.

At least sixty (60) days prior to the commencement of each Period (as identified in the table below) after Period 1, the Parties shall begin negotiation of a Statement of Work for that Period.

During each Period, the Parties shall hold regular meetings (at least monthly) to monitor activity and discuss any changes to or deviations from the Services described in the Statement of Work. Significant changes or deviations must be documented in (i) a Change Order in substantially the form attached hereto as Exhibit C, or (ii) a new Statement of Work.

Period	Dates	Min. Spend during Period		Deposit Amount Applied to Period		Monthly Retainer
1	Jan. 1 – June 30, 2016	$	250,000	$	50,000	$	3,333/mo.
2	July 1 – Dec. 31, 2016	$	400,000	$	80,000 (plus rollover)	$	5,333/mo.
3	Jan. 1 – June 30, 2017	$	500,000	$	100,000 (plus rollover)	$	6,666/mo.
4	July 1 – Dec. 31, 2017	$	500,000		Remainder (inc. rollover)	$	6,666/mo.
5	Jan. 1 – June 30, 2018	$	544,963		Remainder (inc. rollover)	$	7,266/mo.

B. Compensation

This is a Time and Materials contract. Monthly invoices will be provided for Services provided. Payment of each invoice is due within fifteen (15) calendar days of Company’s receipt of such invoice. A late payment penalty of two percent (2%) will be imposed following any payments that are deemed late and will be due immediately.

Rev.1 estimates total labor under the Agreement of $2,455,000 and total expenses under the Agreement of $928,000, for an estimated total of $3,383,000. Company has placed a purchase order with Rev.1 in that amount.

The Company has paid to Rev.1 an initial deposit of $350,000 (the “Deposit”). 10% of each invoice related to the Agreement shall be offset by the Deposit, reducing the Deposit accordingly. As of the start of Period 1 (January 1, 2016), $235,827 of the Deposit remains outstanding.

Page 3 of 8

A portion of the Deposit has been allocated to each Period according to the table above. Any Deposit allocated to a Period and remaining (i.e., not applied against an invoice or forfeited as described below) at the end of the Period shall “roll over” to the next Period, in addition to any Deposit amount allocated to that next Period.

If at the conclusion of a calendar month (i) the Company has not yet used/completed Services for the applicable Period that meet or exceed the Minimum Spend for the applicable Period (as identified above), and (ii) the Company did not request Services for the month that met or exceeded the Monthly Retainer for such calendar month (as identified above), the Company shall owe Rev.1 the Monthly Retainer for such month, and Rev.1 may invoice the Company for such monthly retainer, less the 10% portion that shall be applied against the Deposit as described above. Should the Company receive Services in a subsequent month during the same Period, Rev.1 shall credit Monthly Retainer payments it has received against the invoices for such Services.

If at the conclusion of a Period the Company has not requested Services for the applicable Period that meet or exceed the Minimum Spend for the applicable Period (i) any Deposit amounts that were allocated to such Period (including amounts “rolled over” from previous periods) and remain outstanding shall be forfeited by the Company and considered earned by Rev.1, and (ii) any Monthly Retainer payments applicable to such Period and not credited against Services during the Period shall be forfeited by the Company and considered earned by Rev.1.

The Deposit will be consumed over the term of the Agreement as described above until all projects are complete. Any remaining Deposit will be applied to the final project invoice. Except as provided in Section 5(a), upon conclusion of the Agreement and after payment of the final invoice, any remaining portion of the Deposit will be returned to the Company.

Page 4 of 8

Attachment 2

Exhibit B – Form of Statement of Work

Statement of Work No. _______

This Statement of Work (this “SOW”) dated as of ___________, 201__ (the “Project Effective Date”), is subject to and governed by the Research and Development Services Agreement (the “Agreement”) effective as of March 3, 2015 and amended as of February 17th, 2016, between ONCOSEC Medical Incorporated, a Nevada corporation (“OncoSec”), with a place of business at 5820 Nancy Ridge Drive, San Diego, California 92121, and Rev.1 Engineering Inc., a California corporation (“Rev.1”), having a place of business at 41693 Date Street, Murrieta, California 92562.

All terms used, but not defined in this SOW, shall have the respective meanings set forth in the Agreement.

OncoSec hereby engages Rev.1 to perform the Project described below on the terms and conditions of this SOW and the Agreement. Rev.1 hereby accepts such engagement, and shall perform such Project and otherwise act in strict accordance with the terms and conditions of this SOW and the Agreement.

A. Project Name:

B. Project Effective Date:

C. Project End Date:

D. Services:

a. Project description:

b. Project work product, milestones, and other deliverables:

i.

ii.

iii. Other related Research and Development Services, as requested by OncoSec

E. Project materials and other technology to be provided by OncoSec (if any):

a.

b.

Page 5 of 8

F. Project budget/estimate (attach detailed budget if appropriate):

a.

b.

The term of the Project described herein shall commence on the Project Effective Date and shall continue until the earlier of the date on which the Project is completed or the Project End Date, unless this SOW is terminated by either party upon 10 days’ written notice.

IN WITNESS WHEREOF, the parties hereto have each caused this SOW to be executed by their duly-authorized representatives as of the date first set forth above.

OncoSec Medical Incorporated

By:

Name:

Title:

Rev.1 Engineering Inc.

By:

Name:

Title:

Page 6 of 8

Attachment 3

Exhibit C – Form of Change Order

Change Order No. _______ for Task Order No. _______

This Change Order (this “Change Order”) dated as of ___________, 201__ (the “Change Date”), hereby amends the Task Order No. ___ (the “Task Order”) pursuant to the Research and Development Services Agreement (the “Agreement”) effective as of March 3, 2015 and amended as of February 17th, 2016, between ONCOSEC Medical Incorporated, a Nevada corporation (“OncoSec”), with a place of business at 5820 Nancy Ridge Drive, San Diego, California 92121, and Rev.1 Engineering Inc., a California corporation (“Rev.1”), having a place of business at 41693 Date Street, Murrieta, California 92562.

This Change Order is subject to and governed by the Agreement.

Effective as of the Change Date, the Task Order hereby is amended as follows:

A. Changes to Project End Date:

B. Changes to Services to be performed by Rev.1:

a. Changes to Project description:

b. Changes to Project work product, milestones, and other deliverables:

C. Changes to Project materials and other technology to be provided by OncoSec:

D. Changes to Project budget/estimate:

Except as otherwise expressly amended hereby, the remaining terms and conditions of the Task Order shall remain in full force and effect.

Page 7 of 8

IN WITNESS WHEREOF, the parties hereto have each caused this Change Order to be executed by their duly-authorized representatives as of the date first set forth above.

OncoSec Medical Incorporated

By:

Name:

Title:

Rev.1 Engineering Inc.

By:

Name:

Title:

Page 8 of 8